Inherited Genetic Trait Predicts Resistance to Immunotherapy for Deadly Skin Cancer
NEW YORK, June 5, 2025 /PRNewswire/ -- Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors. Metastatic melanoma, as the disease is formally named, kills nearly 10,000 Americans annually.
While the drugs have proven highly successful in treating metastatic melanoma and several other cancers, the therapies are known to not work for almost half of those who are prescribed them, usually after initial chemotherapy or surgery have failed to stem the growth of new cancer cells.
Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the new study involved a genetic analysis of blood samples from the ongoing landmark CheckMate-067 Phase 3 trial being conducted in over 100 medical centers in 19 countries. Study results showed that patients with a specific type of genetic mutation, called MT haplogroup T (HG-T), were 3.46 times less likely to respond to checkpoint therapy than those without HG-T.
Mutations are changes encoded in the DNA of abnormal or different cells. Researchers found the HG-T changes in immunotherapy-resistant patients' cell powerhouse structures, or mitochondria. Mitochondrial DNA is unique in that it is passed down only from a mother to her offspring, with no genetic contribution or copy from the father, as is traditionally found in a cell's control center, or nuclear DNA. Over time, mitochondrial DNA has evolved worldwide into subgroups labeled from A to Z based on their common mutations.
Publishing in the journal Nature Medicine online June 5, the researchers say they decided to focus on mitochondrial DNA not just because of its unique lineage but also due to previous research showing it played a role in immune cell development.
In the CheckMate trial, immunotherapy drugs, such as nivolumab, were used alone or in combination with another checkpoint inhibitor, ipilimumab, in preventing postsurgical recurrence of melanoma. The drugs work by blocking molecules (the checkpoints) that sit on the surface of immune T cells to keep them from attacking cancer cells like they would invading viruses or bacteria. The body normally uses checkpoints to recognize healthy cells, but in cancer, tumor cells have hijacked and turned off the checkpoints to evade immune system detection. Immunotherapies block checkpoints, making cancer cells more "visible" and vulnerable again to immune cells.
To validate their CheckMate findings, researchers then checked their initial results against samples from 397 metastatic melanoma patients of similar age and gender, whose immunotherapy treatment records were stored at NYU Langone as part of the International Germline Immuno-Oncology Melanoma Consortium (IO-GEM). Results again revealed the same link of immunotherapy resistance to HG-T.
"Checkpoint immunotherapy has become the mainstay in cancer care in the past decade, especially for those with metastatic melanoma, but until now it has never been clearly explained why nearly half will not respond to treatment," said study co-lead investigator and epidemiologist Kelsey Monson, PhD.
"Our study results offer the first scientific evidence of a genetic biomarker, or presence of a mitochondrial mutation known as MT haplogroup T, to help explain why and identify those metastatic melanoma patients who are most likely to not respond to immunotherapy for the disease," said study co-lead investigator and molecular biologist Robert Ferguson, PhD.
"Our findings make possible future testing for the presence of MT haplogroup T to determine which metastatic melanoma patients are most likely to not respond to checkpoint therapy, so other treatment options can be considered, which in turn could improve overall outcomes," said senior study investigator Tomas Kirchhoff, PhD.
"These study results also raise the possibility that other mitochondrial haploid variants could influence which patients respond to other immune therapies," said Kirchhoff, an associate professor in the Department of Population Health at NYU Grossman School of Medicine and a member of the Perlmutter Cancer Center.
Among the study's other key findings was that treatment-resistant HG-T patients had more underdeveloped T cells than nonresistant patients without HG-T. Researchers traced this poor differentiation to increased resilience to reactive oxygen species (ROS), chemicals commonly linked to inflammation, suggesting that HG-T conferred some form of ROS protection that stunted T cell attack.
Kirchhoff says that further experiments are needed to determine the precise role played by mitochondrial genetics, ROS metabolism, and antitumor T cell immunity in cancer therapy. The more immediate next step is a prospective clinical trial to assess whether non-HG-T patients fare better on immunotherapy than patients with HG-T, and whether this applies to other mitochondrial haplogroups and cancers.
Funding for the study was provided by National Institutes of Health grants R01CA227505, F99CA274650, P50CA225450, and P30CA008748, with additional support from Melanoma Research Alliance grant MRA-686192. Further funding support was provided by Italian Ministry of Health Ricerca Corrente grants M2/2 and L1-2. Both drugs used in the CheckMate trial are manufactured by the pharmaceutical company Bristol Myers Squibb, which sponsored the trial and provided the patient specimens and data used in the analysis.
Besides Monson, Ferguson, and Kirchhoff, NYU Langone researchers involved in this study are co-investigators Joanna Handzlik, Leah Morales, Jiahan Xiong, Vylyny Chat, Sasha Dagayev, Alireza Khodadadi-Jamayran, Danny Simpson, Esther Kazlow, Anabelle Bunis, Chaitra Sreenivasaiah, Malid Ibrahim, Iryna Voloshyneya, Yuting Lu, Yongzhao Shao, Michelle Krogsgaard, Janice Mehnart, and Iman Osman.
Other study co-investigators are Wouter Ouwerkerk and Rosalie Luiten, at Amsterdam University Medical Center in the Netherlands; Mariaelena Capone, Gabriele Madonna, and Paolo Ascierto, at the National Tumor Institute Fondazione G. Pascale in Naples, Italy; Anna Pavlick and Hao Tang, at Weill Cornell Medicine in New York; John Haanen, at the Netherlands Cancer Institute in Amsterdam; Sonia Dolfi and Daniel Tenney at Bristol Myers Squibb in Princeton, New Jersey; Thomas Gajewski, at the University of Chicago; Stephen Hodi and Osama Rahma, at Dana-Farber Cancer Institute in Boston; Keith Flaherty and Ryan Sullivan, at Massachusetts General Hospital and Harvard University in Boston; Kasey Couts and William Robinson, at the University of Colorado in Aurora; Igor Puzanov, at Roswell Park Comprehensive Cancer Center in Buffalo, New York; Marc Ernstoff, at the National Cancer Institute in Bethesda, Maryland; Michael Postow, at Memorial Sloan Kettering Cancer Center in New York; and Jason Luke, at the University of Pittsburgh in Pennsylvania.
About NYU Langone Health
NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.
Media ContactDavid March212-404-3528David.March@nyulangone.org
STUDY DOI:10.1038/s41591-025-03699-3
STUDY LINK:https://www.nature.com/articles/s41591-025-03699-3
View original content to download multimedia:https://www.prnewswire.com/news-releases/inherited-genetic-trait-predicts-resistance-to-immunotherapy-for-deadly-skin-cancer-302470861.html
SOURCE NYU Langone Health System
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
6 hours ago
- Boston Globe
Supreme Court finds retired firefighter cannot sue for disability discrimination
Advertisement In a dissent, Justice Ketanji Brown Jackson, joined, in part, by Justice Sonia Sotomayor, argued that the justices had abandoned protections for vulnerable retirees. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'Disabled Americans who have retired from the work force simply want to enjoy the fruits of their labor free from discrimination,' Jackson wrote, adding that Congress had 'plainly protected their right to do so' when it drafted the federal disability rights law. Sotomayor, in a separate writing, argued that a majority of the justices appeared in agreement that retirees may be able to bring disability discrimination claims for actions that occurred while they were still employed. Stanley might have been able to argue that this would apply in her case, too, Sotomayor wrote, but the court had not been asked to weigh in on that question. Advertisement Stanley worked as a firefighter in Sanford, Florida, a city of about 65,000 people northeast of Orlando. When she started her job in 1999, the city offered health insurance until age 65 for two categories of retirees -- those with 25 years of service and those who retired early because of disability. In 2003, the city changed its policy, limiting health insurance to those who retired because of disability to just 24 months of coverage. After nearly two decades, Stanley retired in 2018 at age 47 after she was diagnosed with Parkinson's disease. She expected that the city would continue to pay for most of her health insurance until she turned 65, but it refused, citing its changed policy. Stanley sued, claiming that the city had violated the ADA by providing different benefits to 25-year employees versus those who retired because of a disability. She argued that the city's policy amounted to impermissible discrimination based on disability. A federal trial judge dismissed her claim under the ADA, and the U.S. Court of Appeals for the 11th Circuit agreed. In asking the justices to hear the case, lawyers for Stanley said it could affect millions of disabled Americans who rely on retirement benefits that they earned while employed. One section of the ADA specifies that it is illegal to discriminate in compensation because of a disability. The justices wrestled with whether the section included retirees. Deepak Gupta, a lawyer for Stanley, said in an emailed statement that the decision had created 'a troubling loophole that allows employers to discriminate against retirees simply because they can no longer work due to their disabilities.' Advertisement In her dissent, Jackson wrote that she hoped Congress might step in and provide a 'legislative intervention' to shield other disabled retirees. This article originally appeared in
Atlantic
7 hours ago
- Atlantic
It Has Come to Protein Iced Tea
In the early 1950s, 'Hi-Proteen' powder, one of the first modern protein supplements, hit the market. Initially, it tasted awful. But after its creator, Bob Hoffman, added in Hershey's chocolate, the flavor improved. (He used a canoe paddle to stir his mixture in a giant vat.) Protein products have come a long way since then. Perhaps, they have come too far: Last weekend, at the gym, I was offered a can of lemon-flavored ' protein ice tea.' The summery, yellow-striped packaging advertised 15 grams of protein per can, or about the same as what you might get from three eggs. Apparently protein shakes and protein bars don't cut it anymore. Americans are so obsessed with protein that even an Arnold Palmer comes infused with it. Perhaps protein iced tea was inevitable. Whenever something is trendy, the food industry can't help but push things to the extreme—consider ' plant-based ' peanut butter (as if the spread was not already vegetarian) and gluten-free pumpkin dog biscuits. But even compared with other food trends, the protein situation has gotten out of hand. Just last week, Starbucks announced that it's piloting a high-protein, banana-flavored cold foam. There is protein water, Kardashian-branded protein popcorn, and ' macho ' protein pasta sauce. If you want to get drunk while bulking up, consider a protein-fortified pale ale or a 'Swoleberry' spiked protein seltzer. Nothing is safe from the protein pandemonium. Name a food, and the protein version of it probably exists. Even if you, like me, aren't trying to maximize your protein intake, all of these products can be hard to escape. They have infiltrated every inch of the supermarket: On Monday, I went grocery shopping with the mission of finding the most ridiculous protein-enriched ingredients possible. While preparing my meal, I crunched on ranch-flavored protein tortilla chips (13 grams) and sipped from a bottle of grapefruit-flavored protein water (20 grams). Dinner began with a salad made of 'OrganicGirl Protein Greens,' which feature an assortment of mixed greens including naturally protein-rich sweet-pea leaves (5 grams). My main course was chickpea protein pasta (20 grams) and salmon (40 grams). I topped it all off with a frozen peanut-butter-banana bar for dessert (another 5 grams). In total, I ate more than 170 grams of protein on Monday, or the equivalent of 31 medium eggs. According to the federal government's recommendations, that's almost four times what someone of my build and activity level needs in a day to maintain a ' nutritionally adequate ' diet. The official dietary guidelines suggest that a person needs at least 0.36 grams of protein per pound of body weight to stay healthy. That's not all that much protein. Before my dinner experiment, I had gone through the day without thinking about my protein consumption, and had already surpassed my recommended amount by more than 30 percent. The average American adult regularly exceeds the federal recommendation. So why is protein showing up in iced tea? Some health experts think that the current federal recommendation is insufficient. They believe that for optimal health—to get beyond simply meeting basic nutritional needs—we should be consuming double, if not triple, the recommended amount. Some people—those who strength train, for instance—certainly benefit from increased intake. But for the average person, most experts don't see the point in going wild with protein, as my colleague Katherine J. Wu has written. What makes protein so appealing is that it has been offered as an answer for lots of people's dietary goals. Want to build muscle? Eat protein. Want to feel fuller for longer? Eat protein. Want to lose weight? Eat protein. The nutrient can indeed help with all of those, but sometimes, the claims turn absurd. Cargill, the food giant, recently suggested that protein might help solve broken marriages: 'Protein helps individuals become better parents, partners and employees,' the company wrote in a report this spring. In other words, protein has become synonymous with 'healthy.' The message seems to be resonating: Last year, 71 percent of American adults said they were trying to consume more of it. For food companies, adding protein to virtually everything is an easy way to make their products more alluring. No Starbucks executive is going to suggest a new line of 'fat enhanced' cold foam or iced tea with extra carbs. But extra protein—sure. And that's how we end up in a world of protein mania. The protein shake has given way to protein coffees and protein matchas and protein energy drinks and protein sodas. The protein bar has similarly descended into madness: Last week, Hershey's announced a 'Double Chocolate flavored protein bar' that looks like its normal chocolate bar (Hoffman would be proud). For the purists, there's the recently launched David bar, named after Michelangelo's, which bills itself as 'the most effective portable protein on this planet.' You can eat protein-fortified vanilla glazed donuts for breakfast, top your double cheeseburger with protein-laced ketchup, and finish the day with protein powder mixed with melatonin that promises a good night's sleep. If you're suspicious of these products, it's for good reason. Shoppers might think that certain foods are healthier now that they have a protein label slapped on them. Some of the new products are truly good for you—but eating a ton of protein-packed candy (or even just lots of red meat) comes with health risks that could offset whatever dubious benefit all that added protein might provide. A Snickers bar with 20 grams of protein is still a Snickers bar. By the time I finished my protein dinner, I was starting to feel bloated. Still, I wasn't quite done. I cued up the trailer for Protein, a film that debuted in U.K. cinemas last weekend. The movie tells the story of 'a gym-obsessed serial killer' who 'murders and eats a local drug dealer' for—what else?—protein. I took a bite of a protein-packed double-chocolate cookie and hit 'Play.'
New York Post
9 hours ago
- New York Post
Bill Gates shares ‘next phase of Alzheimer's fight' as he speaks about his father's personal battle
Bill Gates is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. In an essay published this week on his blog at the Microsoft co-founder and tech billionaire, 69, reflected on the difficulty of spending another Father's Day without his dad, Bill Gates Sr. Advertisement The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. 'It was a brutal experience, watching my brilliant, loving father go downhill and disappear,' Gates wrote in the blog post. Today, motivated by his own experience with the common dementia, Gates — who serves as chair of the Gates Foundation — is committed to working toward a cure for the common dementia, which currently affects more than seven million Americans, or one in nine people over 65. In his blog, Gates expressed optimism about the 'massive progress' being made in the fight against Alzheimer's and other dementias. Advertisement Last year, Gates said he visited Indiana University's School of Medicine in Indianapolis to tour the labs where teams have been researching Alzheimer's biomarkers. 5 Bill Gates (left) is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. Brian Ach 'I also got the opportunity to look under the hood of new automated machines that will soon be running diagnostics around the world,' he wrote. 'It's an exciting time in a challenging space.' One of the biggest breakthroughs in Alzheimer's research, according to Gates, is blood-based diagnostic tests, which detect the ratio of amyloid plaques in the brain. (Amyloid plaques, clumps of protein that accumulate in the brain, are one of the hallmarks of Alzheimer's.) Advertisement 'I'm optimistic that these tests will be a game-changer,' Gates wrote. 5 The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. Bloomberg via Getty Images Last month, the U.S. Food and Drug Administration (FDA) approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. Traditionally, Gates noted, the primary path to Alzheimer's diagnosis was either a PET scan (medical imaging) or spinal tap (lumbar puncture), which were usually only performed when symptoms emerged. Advertisement The hope is that blood-based tests could do a better job of catching the disease early, decline begins. 5 Last month, the U.S. Food and Drug Administration approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. – 'We now know that the disease begins 15 to 20 years before you start to see any signs,' Gates wrote. 'A simple, accurate and easy-to-run blood test might one day make routine screening possible, identifying patients long before they experience cognitive decline,' he stated. Gates said he is often asked, 'What is the point of getting diagnosed if I can't do anything about it?' Start and end your day informed with our newsletters Morning Report and Evening Update: Your source for today's top stories Thanks for signing up! Enter your email address Please provide a valid email address. By clicking above you agree to the Terms of Use and Privacy Policy. Never miss a story. Check out more newsletters To that end, he expressed his optimism for the future of Alzheimer's treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval. 'Both have proven to modestly slow down the progression of the disease, but what I'm really excited about is their potential when paired with an early diagnostic,' Gates noted. Advertisement He said he is also hopeful that the blood tests will help speed up the process of enrolling patients in clinical trials for new Alzheimer's drugs. 5 The hope is that blood-based tests could do a better job of catching the disease early, decline begins. Monkey Business – To accomplish this, Gates is calling for increased funding for research, which often comes from federal grants. 'This is the moment to spend more money on research, not less,' he wrote, also stating that 'the quest to stop Alzheimer's has never had more momentum.' Advertisement 'There is still a huge amount of work to be done — like deepening our understanding of the disease's pathology and developing even better diagnostics,' Gates went on. 5 Microsoft Chairman Bill Gates, his wife Melinda, far left, his father Bill Gates Sr., and his step-mother Mimi Gates pose for a photo in 2007. AP Gates pointed out that when his father had Alzheimer's, it was considered a 'death sentence,' but that is starting to change. Advertisement 'I am blown away by how much we have learned about Alzheimer's over the last couple of years,' he wrote. 'I cannot help but be filled with a sense of hope when I think of all the progress being made on Alzheimer's, even with so many challenges happening around the world. We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease.'
